BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Łobocka M, Dąbrowska K, Górski A. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future. BioDrugs 2021;35:255-80. [PMID: 33881767 DOI: 10.1007/s40259-021-00480-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Miroshnikov KA, Evseev PV, Lukianova AA, Ignatov AN. Tailed Lytic Bacteriophages of Soft Rot Pectobacteriaceae. Microorganisms 2021;9:1819. [PMID: 34576713 DOI: 10.3390/microorganisms9091819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Amankwah S, Abdella K, Kassa T. Bacterial Biofilm Destruction: A Focused Review On The Recent Use of Phage-Based Strategies With Other Antibiofilm Agents. Nanotechnol Sci Appl 2021;14:161-77. [PMID: 34548785 DOI: 10.2147/NSA.S325594] [Reference Citation Analysis]
3 Cass J, Barnard A, Fairhead H. Engineered Bacteriophage as a Delivery Vehicle for Antibacterial Protein, SASP. Pharmaceuticals (Basel) 2021;14:1038. [PMID: 34681262 DOI: 10.3390/ph14101038] [Reference Citation Analysis]
4 Kowalski J, Górska R, Cieślik M, Górski A, Jończyk-matysiak E. What Are the Potential Benefits of Using Bacteriophages in Periodontal Therapy? Antibiotics 2022;11:446. [DOI: 10.3390/antibiotics11040446] [Reference Citation Analysis]
5 Podlacha M, Grabowski Ł, Kosznik-Kawśnicka K, Zdrojewska K, Stasiłojć M, Węgrzyn G, Węgrzyn A. Interactions of Bacteriophages with Animal and Human Organisms-Safety Issues in the Light of Phage Therapy. Int J Mol Sci 2021;22:8937. [PMID: 34445641 DOI: 10.3390/ijms22168937] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Swietnicki W. Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens. Biomolecules 2021;11:892. [PMID: 34203937 DOI: 10.3390/biom11060892] [Reference Citation Analysis]
7 Ryu S. Grand Challenges in Phage Biology. Front Microbiol 2021;12:715039. [PMID: 34305882 DOI: 10.3389/fmicb.2021.715039] [Reference Citation Analysis]
8 Schwarz C, Mathieu J, Laverde Gomez JA, Yu P, Alvarez PJJ. Renaissance for Phage-Based Bacterial Control. Environ Sci Technol 2021. [PMID: 34793127 DOI: 10.1021/acs.est.1c06232] [Reference Citation Analysis]
9 Barnard AML, Fairhead HIM. A commentary on the development of engineered phage as therapeutics. Drug Discov Today 2021:S1359-6446(21)00286-5. [PMID: 34237459 DOI: 10.1016/j.drudis.2021.06.013] [Reference Citation Analysis]
10 Choi YJ, Kim S, Bae S, Kim Y, Chang HH, Kim J. Antibacterial Effects of Recombinant Endolysins in Disinfecting Medical Equipment: A Pilot Study. Front Microbiol 2021;12:773640. [PMID: 35310392 DOI: 10.3389/fmicb.2021.773640] [Reference Citation Analysis]
11 Barnard AML, Cass JA. Targetable nano-delivery vehicles to deliver anti-bacterial small acid-soluble spore protein (SASP) genes. Emerg Top Life Sci 2021;5:637-41. [PMID: 34723318 DOI: 10.1042/ETLS20210147] [Reference Citation Analysis]
12 Cater K, Międzybrodzki R, Morozova V, Letkiewicz S, Łusiak-Szelachowska M, Rękas J, Weber-Dąbrowska B, Górski A. Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections. Antibiotics (Basel) 2021;10:1030. [PMID: 34572612 DOI: 10.3390/antibiotics10091030] [Reference Citation Analysis]